Navigation Links
Trius Doses First Patient in Antibacterial Phase 2 Trial
Date:9/21/2008

TR-701 Tested for Efficacy in Drug Resistant Skin Infections

SAN DIEGO, Sept. 22 /PRNewswire/ -- Trius Therapeutics, Inc. today announced the initiation of Phase 2 testing of the oral form of its second-generation oxazolidinone antibacterial drug TR-701. The multicenter trial will test the efficacy, safety and tolerability of once-daily doses of 200, 300 and 400 milligrams of TR-701 in complicated skin and skin structure infections (cSSSI) for five to seven days of treatment.

The study follows the recently completed two-part Phase 1 study that tested the safety, tolerability and pharmacokinetics of TR-701 in single and multiple ascending doses for up to 21 days compared with Zyvox(R) (linezolid), the only marketed drug of the oxazolidinone class. In addition, separate food effect and microdialysis studies measuring the absorption of TR-701 in the presence and absence of food and the tissue penetration of the drug, respectively, have also been completed.

Results of the Phase 1 trials will be presented at the joint annual meetings of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and the Infectious Diseases Society of America (IDSA) in Washington, D.C in October 2008.

"Our Phase 1 study results indicate that TR-701 will be a once-daily drug with the potential to offer patients several important advantages over linezolid as well as other marketed drugs," said Philippe Prokocimer, M.D., Chief Medical Officer of Trius. "The intent of Phase 2 will be to validate these observations in a patient population and to select a therapeutic dosing regimen from the three doses being tested."

"The growing epidemic of MRSA in the hospital and community leaves few viable treatment options for patients requiring an oral drug," said Jeffrey Stein, Ph.D., Chief Executive Officer of Trius. "We believe that the once-daily dosing and short course of TR-701 therapy of five to seven days will offer a clinical advantage fo
'/>"/>

SOURCE Trius Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. PacificGMP Completes GMP Product Fill for Trius Therapeutics
2. Trius Initiates U.S. Phase I Trial for its Oxazolidinone Antibacterial Drug, TR-701
3. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
4. Sanofi Pasteur Shipping First Doses of Influenza Vaccine for the 2008-2009 Season in the US
5. Video: Resveratrol-based Nutriceutical (Longevinex(R)) Induces Favorable Changes on Gene Expression in Mouse Heart At Doses 17-320 Times Lower Than Prior Studies
6. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
7. Sanofi Pasteur to Donate 60 Million Doses of H5N1 Vaccine to WHO Over 3 Years for its Influenza Vaccine Global Stockpile
8. NuRx Pharmaceuticals Doses First Patient in Phase I Clinical Trial of First-in-Class RXR Agonist NRX4204
9. Emisphere Announces Second Study Demonstrating Dramatic Increases in Absorption of Oral B12 Using eligen(R) Technology at Lower Doses
10. Takeda Doses First Patient in a U.S. Phase 1 Study of Hematide(TM) to Treat Chemotherapy Induced Anemia
11. QRxPharma Doses First Patients in Phase III Clinical Trial Program for its Dual Opioid Pain Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 2014 Moms are ready to live the ... and their kids, according to the results of the ... Go Mobile for Moms, the latest installment in BabyCenter,s ... 1 pregnancy and parenting web and mobile destination worldwide, ... moms surveyed say they can,t think of a reason ...
(Date:10/22/2014)... 2014 AVACEN Medical announced today that its ... OTC clearance by the U.S. Food and Drug Administration. ... over the Internet for: the temporary relief of ... strains and sprains . Logo - ... $2495) is a sophisticated medical device incorporating over 3,000 ...
(Date:10/22/2014)... 2014  CryoLife, Inc. (NYSE: CRY ), ... on cardiac and vascular surgery, announced today that ... Officer, has been elected to the Company,s Board of ... G. Anderson , Executive Chairman of CryoLife, stated, "Since joining ... an excellent leader who is well positioned to maximize ...
Breaking Medicine Technology:BabyCenter Finds Mom Ready to Live the "Measured Life" in its U.S. Mobile Mom 2014 Report: Health & Fitness Go Mobile for Moms 2BabyCenter Finds Mom Ready to Live the "Measured Life" in its U.S. Mobile Mom 2014 Report: Health & Fitness Go Mobile for Moms 3BabyCenter Finds Mom Ready to Live the "Measured Life" in its U.S. Mobile Mom 2014 Report: Health & Fitness Go Mobile for Moms 4AVACEN Medical Announces FDA Clearance of First Medical Device with Internal Game Mode 2Pat Mackin Joins CryoLife Board of Directors 2Pat Mackin Joins CryoLife Board of Directors 3
... 1, 2011 SI-BONE, Inc. (San Jose, California), a medical ... (SI) joint, announced today that it is launching an intensive ... corporate initiative to generate a substantial body of clinical and ... of this effort is MISSION ( M inimally I ...
... 1, 2011 eResearchTechnology, Inc. (ERT), (Nasdaq: ... services and customizable medical devices to biopharmaceutical and ... safety and respiratory efficacy services in drug development, ... June 30, 2011.  Unless otherwise noted, all comparative ...
Cached Medicine Technology:SI-BONE Announces Global Clinical Strategy for Minimally Invasive iFuse Sacroiliac Joint Fusion 2SI-BONE Announces Global Clinical Strategy for Minimally Invasive iFuse Sacroiliac Joint Fusion 3SI-BONE Announces Global Clinical Strategy for Minimally Invasive iFuse Sacroiliac Joint Fusion 4ERT Reports Second Quarter 2011 Operating Results 2ERT Reports Second Quarter 2011 Operating Results 3ERT Reports Second Quarter 2011 Operating Results 4ERT Reports Second Quarter 2011 Operating Results 5ERT Reports Second Quarter 2011 Operating Results 6ERT Reports Second Quarter 2011 Operating Results 7ERT Reports Second Quarter 2011 Operating Results 8ERT Reports Second Quarter 2011 Operating Results 9ERT Reports Second Quarter 2011 Operating Results 10ERT Reports Second Quarter 2011 Operating Results 11ERT Reports Second Quarter 2011 Operating Results 12ERT Reports Second Quarter 2011 Operating Results 13
(Date:10/22/2014)... Best Cheap Hosting USA is among ... site has recently announced that iPower ( http://www.best-cheap-hosting-usa.com/go/iPower/ ) ... from around the world. , “iPower is one of ... is providing various kinds of useful products for new ... offering excellent customer service and a number of features ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 Losing Weight Your ... industry is staring you in the face, it certainly can ... not do your body an extra favor by doing it ... tempting crash diets. Instead, listen to your body, exercise regularly, ... Exercise is essential to losing weight; you need to exercise ...
(Date:10/22/2014)... 2014 Lintelus, Inc., an event software ... of Sales, will be speaking on the subject of ... on October 28, at the Holiday Inn in New ... as well as a Tech Demo at 12:45pm, to ... a more engaging event experience. , The Annual Meetings ...
(Date:10/22/2014)... WALTHAM, MA (PRWEB) October 22, 2014 ... developing new solutions for the treatment of bacterial infections, ... J. Sinskey has joined its board of directors. ... Microbiology and Engineering Systems at The Massachusetts Institute of ... the MIT faculty since 1968. Dr. Sinskey also holds ...
(Date:10/22/2014)... Maureen Salamon HealthDay Reporter ... women undergoing in vitro fertilization (IVF) are only about half ... popular assisted reproduction technique, new research indicates, and the racial ... the study, about 31 percent of white patients became pregnant ... Analyzing more than 4,000 IVF cycles over two years ...
Breaking Medicine News(10 mins):Health News:Best Cheap Hosting USA Has Recently Announced The Best Cheap Web Hosting Companies In 2014 2Health News:ReductionGuruMD Presents Ways to Improve Your Weight Loss Results 2Health News:Jay Cormier, Sr. Vice President of Sales for Lintelus, Speaks about Event Technology Integration at Meetings Technology Expo in NYC 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 3
... Society,s Medal of Honor to be Awarded on November 21 ... Nov. 21 The American Cancer Society -- the nation,s ... research and discovery -- will present its highest honor, the ... contributions to the fight against cancer. This year,s winners, who ...
... Mass., Nov. 21 NxStage Medical, Inc.,(Nasdaq: ... today,announced that it ranked 14th on Deloitte,s 2008 Technology ... media, telecommunications and,life sciences companies in North America. Rankings ... five years, from 2003-2007. NxStage Medical,Inc. grew more than ...
... 61st Annual Scientific Meeting of the Gerontological Society of ... & Co., Inc., significantly reduced blood sugar levels in ... associated with hypoglycemia (low blood sugar). In this study ... were no reports of hypoglycemia in either the JANUVIA ...
... Baker and members of the St. Petersburg City Council are ... on its Faces of Influenza initiative to educate ... of annual vaccination to help protect themselves and their loved ... In support of the initiative, Mayor Baker, Council ...
... from other known species , , FRIDAY, Nov. 21 (HealthDay News) ... been identified by American and Ugandan scientists. , The ... in western Uganda in 2007. It is genetically distinct from ... 30 percent at the genetic level, said the scientists from ...
... Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ) today ... from The Nasdaq Stock Market ("Nasdaq") stating that the ... 4310(c)(3), which requires the Company to have a minimum ... of listed securities, or $500,000 of net income from ...
Cached Medicine News:Health News:The Honorable Edward M. Kennedy, Scientists Mina J. Bissell and Susan Band Horwitz, and Philanthropist Jon M. Huntsman to Receive American Cancer Society Highest Honor for Outstanding Contributions to Cancer Fight 2Health News:The Honorable Edward M. Kennedy, Scientists Mina J. Bissell and Susan Band Horwitz, and Philanthropist Jon M. Huntsman to Receive American Cancer Society Highest Honor for Outstanding Contributions to Cancer Fight 3Health News:The Honorable Edward M. Kennedy, Scientists Mina J. Bissell and Susan Band Horwitz, and Philanthropist Jon M. Huntsman to Receive American Cancer Society Highest Honor for Outstanding Contributions to Cancer Fight 4Health News:The Honorable Edward M. Kennedy, Scientists Mina J. Bissell and Susan Band Horwitz, and Philanthropist Jon M. Huntsman to Receive American Cancer Society Highest Honor for Outstanding Contributions to Cancer Fight 5Health News:The Honorable Edward M. Kennedy, Scientists Mina J. Bissell and Susan Band Horwitz, and Philanthropist Jon M. Huntsman to Receive American Cancer Society Highest Honor for Outstanding Contributions to Cancer Fight 6Health News:NxStage(R) Ranked 14th Fastest Growing Company in North America on Deloitte's 2008 Technology Fast 500 2Health News:NxStage(R) Ranked 14th Fastest Growing Company in North America on Deloitte's 2008 Technology Fast 500 3Health News: New Study Data: JANUVIA™ (sitagliptin) Significantly Reduced Blood Sugar Levels and Was Not Associated with Hypoglycemia in Elderly Patients with Type 2 Diabetes 2Health News: New Study Data: JANUVIA™ (sitagliptin) Significantly Reduced Blood Sugar Levels and Was Not Associated with Hypoglycemia in Elderly Patients with Type 2 Diabetes 3Health News: New Study Data: JANUVIA™ (sitagliptin) Significantly Reduced Blood Sugar Levels and Was Not Associated with Hypoglycemia in Elderly Patients with Type 2 Diabetes 4Health News: New Study Data: JANUVIA™ (sitagliptin) Significantly Reduced Blood Sugar Levels and Was Not Associated with Hypoglycemia in Elderly Patients with Type 2 Diabetes 5Health News: New Study Data: JANUVIA™ (sitagliptin) Significantly Reduced Blood Sugar Levels and Was Not Associated with Hypoglycemia in Elderly Patients with Type 2 Diabetes 6Health News: New Study Data: JANUVIA™ (sitagliptin) Significantly Reduced Blood Sugar Levels and Was Not Associated with Hypoglycemia in Elderly Patients with Type 2 Diabetes 7Health News: New Study Data: JANUVIA™ (sitagliptin) Significantly Reduced Blood Sugar Levels and Was Not Associated with Hypoglycemia in Elderly Patients with Type 2 Diabetes 8Health News: New Study Data: JANUVIA™ (sitagliptin) Significantly Reduced Blood Sugar Levels and Was Not Associated with Hypoglycemia in Elderly Patients with Type 2 Diabetes 9Health News: New Study Data: JANUVIA™ (sitagliptin) Significantly Reduced Blood Sugar Levels and Was Not Associated with Hypoglycemia in Elderly Patients with Type 2 Diabetes 10Health News: New Study Data: JANUVIA™ (sitagliptin) Significantly Reduced Blood Sugar Levels and Was Not Associated with Hypoglycemia in Elderly Patients with Type 2 Diabetes 11Health News: New Study Data: JANUVIA™ (sitagliptin) Significantly Reduced Blood Sugar Levels and Was Not Associated with Hypoglycemia in Elderly Patients with Type 2 Diabetes 12Health News: New Study Data: JANUVIA™ (sitagliptin) Significantly Reduced Blood Sugar Levels and Was Not Associated with Hypoglycemia in Elderly Patients with Type 2 Diabetes 13Health News: New Study Data: JANUVIA™ (sitagliptin) Significantly Reduced Blood Sugar Levels and Was Not Associated with Hypoglycemia in Elderly Patients with Type 2 Diabetes 14Health News: New Study Data: JANUVIA™ (sitagliptin) Significantly Reduced Blood Sugar Levels and Was Not Associated with Hypoglycemia in Elderly Patients with Type 2 Diabetes 15Health News: New Study Data: JANUVIA™ (sitagliptin) Significantly Reduced Blood Sugar Levels and Was Not Associated with Hypoglycemia in Elderly Patients with Type 2 Diabetes 16Health News: New Study Data: JANUVIA™ (sitagliptin) Significantly Reduced Blood Sugar Levels and Was Not Associated with Hypoglycemia in Elderly Patients with Type 2 Diabetes 17Health News: New Study Data: JANUVIA™ (sitagliptin) Significantly Reduced Blood Sugar Levels and Was Not Associated with Hypoglycemia in Elderly Patients with Type 2 Diabetes 18Health News: New Study Data: JANUVIA™ (sitagliptin) Significantly Reduced Blood Sugar Levels and Was Not Associated with Hypoglycemia in Elderly Patients with Type 2 Diabetes 19Health News: New Study Data: JANUVIA™ (sitagliptin) Significantly Reduced Blood Sugar Levels and Was Not Associated with Hypoglycemia in Elderly Patients with Type 2 Diabetes 20Health News: New Study Data: JANUVIA™ (sitagliptin) Significantly Reduced Blood Sugar Levels and Was Not Associated with Hypoglycemia in Elderly Patients with Type 2 Diabetes 21Health News: New Study Data: JANUVIA™ (sitagliptin) Significantly Reduced Blood Sugar Levels and Was Not Associated with Hypoglycemia in Elderly Patients with Type 2 Diabetes 22Health News: New Study Data: JANUVIA™ (sitagliptin) Significantly Reduced Blood Sugar Levels and Was Not Associated with Hypoglycemia in Elderly Patients with Type 2 Diabetes 23Health News: New Study Data: JANUVIA™ (sitagliptin) Significantly Reduced Blood Sugar Levels and Was Not Associated with Hypoglycemia in Elderly Patients with Type 2 Diabetes 24Health News: New Study Data: JANUVIA™ (sitagliptin) Significantly Reduced Blood Sugar Levels and Was Not Associated with Hypoglycemia in Elderly Patients with Type 2 Diabetes 25Health News: New Study Data: JANUVIA™ (sitagliptin) Significantly Reduced Blood Sugar Levels and Was Not Associated with Hypoglycemia in Elderly Patients with Type 2 Diabetes 26Health News: New Study Data: JANUVIA™ (sitagliptin) Significantly Reduced Blood Sugar Levels and Was Not Associated with Hypoglycemia in Elderly Patients with Type 2 Diabetes 27Health News: New Study Data: JANUVIA™ (sitagliptin) Significantly Reduced Blood Sugar Levels and Was Not Associated with Hypoglycemia in Elderly Patients with Type 2 Diabetes 28Health News: New Study Data: JANUVIA™ (sitagliptin) Significantly Reduced Blood Sugar Levels and Was Not Associated with Hypoglycemia in Elderly Patients with Type 2 Diabetes 29
Hook Shaped Tip , Curved to the Left; with 30 cm long silicone tubing with connector; overall length 40mm; stainless steel...
5x6mm Loop, 2 Irrigation Ports at 10, 2 O'Clock, 18 Gauge Thin Walled 1.2mm Shaft; overall length 40mm; stainless steel...
HYDRACLEAR is our brandname for a remarkable moisture rich element that lies throughout the interior and exterior of the ACUVUE ADVANCE Brand Contact Lenses creating a unique soft, silky feel....
4-Strand Basket Retriever was developed to facilitate recovery of foreign objects from within the neuro, peripheral, and cardiovasculature, the In-Time Retrieval Device features an integrated corewir...
Medicine Products: